Pre-order here

The acquisition is being covered as a story about the race to own “immune system reset” technology. That read is correct. But the most important commercial logic embedded in this deal has not appeared in any coverage published so far.

Subscribe now

What happened

On May 3, 2026, UCB, the Belgian biopharmaceutical company, announced an agreement to acquire Candid Therapeutics for $2 billion upfront, with up to $200 million in additional milestone payments. Total deal consideration: up to $2.2 billion. The transaction is expected to close by end of Q2 to early Q3 2026.

Candid Therapeutics is a US-based clinical-stage company developing a new class of autoimmune drugs. Its lead asset, cizutamig, works by directing the body’s own immune cells to identify and destroy the specific cells responsible for producing the antibodies that drive autoimmune disease and effectively clearing the source of the problem rather than suppressing the immune system broadly.

As of the acquisition announcement, more than 100 patients had received cizutamig, including 68 with autoimmune diseases. Global Phase 2 studies are planned in myasthenia gravis and interstitial lung disease. Earlier-stage evaluation is also underway across additional autoimmune indications including lupus, rheumatoid arthritis, systemic sclerosis-associated disease, and IgA nephropathy.

UCB describes the acquisition as part of a platform-driven strategy in next-generation immunology — a deliberate move to own multiple targeting approaches before the field matures.

Why it matters

The coverage this week is framing this as a story about platform immunology. Two billion dollars for a clinical-stage company with a novel mechanism, before pivotal proof. A high-conviction bet on the thesis that if you can eliminate the cells producing the antibodies that drive autoimmune disease, you may produce durable remission rather than managing symptoms indefinitely. That read is accurate. It is also incomplete.

The most important commercial logic embedded in this deal has not appeared in any coverage published this week. In this edition I will name it, explain why it changes how capital allocators should read the acquirer landscape in this space, and deliver six observations on where to be positioned before the next announcement; three on what the deal signals now, and three on what to track as the thesis develops.

Read more

Pre-order here

Veozah launched in 2023 as the first non-hormonal oral treatment for menopause symptoms. Two and a half years later, the commercial revolution the category promised has not arrived. Bayer launched its competitor anyway. Here is what that tells capital allocators.

Subscribe now

What happened

In May 2023, Astellas’ Veozah became the first FDA-approved non-hormonal oral treatment for the hot flashes and night sweats affecting approximately 75% of women during the menopause transition. Astellas projected US revenues of $375 million in the drug’s first year of commercialisation.

In FY2024, its second full year on market, Veozah generated approximately $220 million globally. In December 2024, the FDA added a black box warning for rare but serious liver injury; the most prominent safety flag the agency can attach to a prescription drug.

Fast forward to October 2025 and Bayer’s Lynkuet received FDA approval for the same indication. It targets both the NK1 and NK3 receptors, a dual mechanism that Veozah does not carry. Importantly, it has no black box warning. Bayer made it commercially available in November 2025 and estimates annual peak sales of approximately €1 billion.

In April 2026, BioPharma Dive published a survey of persistent structural barriers in women's health drug development, noting that despite two approved non-hormonal drugs and a large unaddressed patient population, Veozah has faced slower-than-expected sales and reimbursement complications.

Why it matters

The coverage this week is framing this as a competitive story. Two drugs, same indication, different mechanisms. One with a cleaner safety profile. The question most coverage is asking is which company wins the menopause hot flash market.

That is the wrong question for capital allocators and in this piece, I will cover the one development most coverage has missed entirely, and share three observations on what this category dynamic tells capital allocators in women’s health about where to be positioned before the next announcement.

Read more

Pre-order here

The largest overseas acquisition in Indian pharmaceutical history transferred the world's biggest dedicated women's health portfolio to a biosimilar manufacturer. Here is what that means for where the exits go from here.

Subscribe now

What happened

On 26 April 2026, Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion. The offer price of $14 per share represents a 24% premium to Organon’s closing price the previous Friday. The deal is the largest overseas acquisition in Indian pharmaceutical history.

The transaction transfers Organon’s full portfolio to Sun: Nexplanon, the world’s leading contraceptive implant; NuvaRing; Follistim for fertility; and a biosimilar portfolio including Hadlima and Renflexis. It also transfers Organon’s commercial infrastructure in China, where the company generates more than $800 million in annual revenue.

Combined, the two entities are projected to generate approximately $12.4 billion in revenue, placing the merged group among the 25 largest pharmaceutical companies globally.

Sun Pharma anticipates becoming a top-three global player in women’s health and the seventh-largest biosimilar company worldwide. The deal is expected to close in early 2027, pending regulatory approvals and shareholder consent.

Why it matters

Read more

Pre-order here

Gilead just paid $5 billion for a Munich biotech company. The deal was announced on Monday. The people who benefited from it were positioned years ago and in this article, I'm breaking down the signals they were watching so you know how to find the next one before the announcement.

Subscribe now

What happened

Gilead first partnered with Tubulis in December 2024 under an option and license agreement worth up to $465 million. Sixteen months later it didn’t just exercise the option. It bought the company.

What happened in between matters. Tubulis reported a 59% overall response rate in platinum-resistant ovarian cancer — an indication with no adequate standard of care and a patient population chronically underserved by both clinical investment and capital attention. The data moved Gilead from partner to acquirer.

And Gilead wasn’t the first major US strategic to take notice. BMS had also licensed Tubulis technology in 2023 for over $1 billion in milestones. Two of the world’s largest pharmaceutical companies had independently validated the same European platform.

Why it matters

US public R&D funding is under sustained structural pressure. Large pharma cannot rebuild deep-tech platform capability internally at the pace the competitive landscape demands. The efficient path (and Gilead has taken it three times this year alone) is acquisition of platform assets that have absorbed early-stage risk, demonstrated clinical signal, and retained scientific talent onshore. Tubulis is the European chapter of that strategy.

But here is the read that most coverage is missing this week.

When BMS licensed Tubulis technology in 2023, they validate the platform with that signal. When Gilead partnered sixteen months later, the auction had effectively started; it just hadn’t been announced yet.

That pattern — strategic partnership as a structured private option, clinical data as the conversion trigger, acquisition as the public confirmation — is not unique to Tubulis. It is how large pharma has been systematically acquiring European deep-tech biotech for the better part of a decade.

It just rarely happens at this scale, with this speed, and with a women’s health indication (ovarian cancer) anchoring the lead program.

That last fact is the one worth sitting with. The women’s health indication didn’t discount this exit. It justified it and that distinction is about to matter for every European platform asset currently sitting at Series B or C with a gynecologic oncology program in the lead position.

What this signals for investors

The most important thing about the Tubulis exit isn’t the size.

Read more

Pre-order here

The most important acquirer in women’s health pharmaceuticals is subtly telling the market what it has become. Its not doing so through a press release but rather through a sequence of decisions made between October 2025 and March 2026 that, read together, paint a specific picture. Most investors in this space are reading them separately and that is the gap.

Organon, the MSD spin-out that holds Nexplanon, NuvaRing, and one of the largest women’s health commercial footprints in the world has spent the last five months selling assets, dropping R&D programs, licensing commercial-stage devices, running without a permanent CEO, and watching its share price sit roughly 63% below its three-year high. A non-binding acquisition approach from Sun Pharma surfaced in January, was publicly labelled speculative within days, and has since gone quiet.

What happened

Between October 2025 and March 2026, Organon:

• lost its founding CEO to a Nexplanon sales irregularity investigation

• reported full-year 2025 revenue of $6.2B against $8.64B in debt

• cut its quarterly dividend to $0.02

• discontinued its entire internal R&D pipeline for endometriosis and PCOS (both acquired via Forendo in 2021)

• divested its JADA postpartum hemorrhage system for $465M

• and licensed in MIUDELLA, the first new hormone-free copper IUD in the US in 40 years for $27.5M upfront.

In addition, guidance for FY 2026 is flat and the permanent CEO search is ongoing.

Why it matters

What Organon’s portfolio moves reveal is a deliberate strategic retreat: from originating science in women’s conditions toward distributing and commercialising proven products.

That is a rational response to $8.64B in debt and a governance crisis. It is also a structural shift in what Organon is and what it can offer the ecosystem that has been building toward it as an acquirer.

The endometriosis and PCOS pipeline drops are worth sitting with. These are two of the highest-unmet-need, highest-diagnostic-delay conditions in women’s health. Organon acquired rights to drug candidates in both, and has now walked away from both. At the same time, it licensed a commercial-stage contraceptive device.

That sequencing tells you something precise about what Organon is becoming. The more important question for anyone building or backing companies in this space is what that becoming means for where exits go from here.

Read more

Pre-order here

Read more

Subscribe now

This newsletter is 100% free. But it takes hours each week to research, write, and produce a…

Read more

Read more

Read more

Read more

From the FDA greenlighting the first self-collected cervical cancer screening device, to FemTech markets attracting new capital with global traction, the contours of…

Read more

From biotech acquisitions in ovarian aging to the institutional signaling power of the Milken Institute, this isn’t hype. It’s architecture. The scaffolding is going …

Read more

From autoimmune therapies to maternal mental health partnerships, the landscape is broadening. And for those paying close attention, the opportunity is growing wider, deeper, and harder to…

Read more

Read more

Read more

Read more